Efficacy and safety of cyclin ‐dependent kinase 4/6 inhibitor in patients with advanced breast cancer: A real‐world experience

ConclusionCDK4/6i administered in a real-world setting exhibits a similar survival benefit with the clinical trials.

Source: Thoracic Cancer - September 5, 2023 Category: Cancer & Oncology Authors: Tzu ‐Rong Peng, Jia‐Hui Chen, Ta‐Wei Wu Tags: ORIGINAL ARTICLE Source Type: research